Nautilus Biotechnology (NASDAQ:NAUT) Reaches New 1-Year High – What’s Next?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $4.24 and last traded at $4.0440, with a volume of 119801 shares. The stock had previously closed at $3.95.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on NAUT. Guggenheim increased their price objective on Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Nautilus Biotechnology Trading Down 3.3%

The stock has a market capitalization of $478.40 million, a price-to-earnings ratio of -8.04 and a beta of 1.45. The company’s 50 day moving average is $2.47 and its 200 day moving average is $1.85.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

Insider Activity

In other news, CEO Sujal M. Patel bought 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was purchased at an average cost of $2.61 per share, with a total value of $65,250.00. Following the transaction, the chief executive officer directly owned 10,366,721 shares in the company, valued at $27,057,141.81. This trade represents a 0.24% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 41.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Clarius Group LLC lifted its stake in Nautilus Biotechnology by 14.1% in the third quarter. Clarius Group LLC now owns 1,209,646 shares of the company’s stock valued at $1,022,000 after buying an additional 149,186 shares during the last quarter. Millennium Management LLC grew its position in shares of Nautilus Biotechnology by 5.4% during the fourth quarter. Millennium Management LLC now owns 1,019,996 shares of the company’s stock worth $1,989,000 after acquiring an additional 52,448 shares during the last quarter. Sentinel Trust Co. LBA acquired a new position in shares of Nautilus Biotechnology in the 4th quarter valued at $1,462,000. Geode Capital Management LLC increased its holdings in shares of Nautilus Biotechnology by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 560,909 shares of the company’s stock valued at $1,094,000 after acquiring an additional 7,307 shares during the period. Finally, Corient Private Wealth LLC raised its position in Nautilus Biotechnology by 860.0% in the 2nd quarter. Corient Private Wealth LLC now owns 435,350 shares of the company’s stock valued at $316,000 after purchasing an additional 390,000 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.